| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/18/2010 | EP2218453A1 Antioxidant dietary supplement |
| 08/18/2010 | EP2218452A1 Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis |
| 08/18/2010 | EP2218451A1 Use of FTS for treating malignant disorders |
| 08/18/2010 | EP2218450A1 Memantine for treating bipolar mood disorders resistant to conventional treatments |
| 08/18/2010 | EP2218448A2 Oral drug delivery system comprising high viscosity liquid carrier materials |
| 08/18/2010 | EP2218444A2 Delayed release rasagiline formulation |
| 08/18/2010 | EP2218443A1 Orally disintegrating tablet |
| 08/18/2010 | EP2218424A1 Intraocular drug delivery systems |
| 08/18/2010 | EP2218342A2 Novel nutraceutical compositions and use thereof |
| 08/18/2010 | EP2218337A1 Mimicking the metabolic effects of caloric restriction by administration of glucose anti-metabolites |
| 08/18/2010 | EP2217706A2 Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer |
| 08/18/2010 | EP2217697A1 Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
| 08/18/2010 | EP2217613A1 Binding of pathological forms of proteins using conjugated polyelectrolytes |
| 08/18/2010 | EP2217611A1 Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors |
| 08/18/2010 | EP2217610A1 Antibacterial aminoglycoside analogs |
| 08/18/2010 | EP2217606A1 Solubilized thiazolopyridines |
| 08/18/2010 | EP2217605A1 Compounds for inhibiting ksp kinesin activity |
| 08/18/2010 | EP2217603A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
| 08/18/2010 | EP2217601A1 Imidazopyridazines for use as protein kinase inhibitors |
| 08/18/2010 | EP2217599A1 Alpha-fluoroalkyl tetrabenazine and dihydrotetrabenazine imaging agents and probes |
| 08/18/2010 | EP2217598A1 New tetracyclic compounds |
| 08/18/2010 | EP2217597A1 Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease |
| 08/18/2010 | EP2217596A2 Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119 |
| 08/18/2010 | EP2217595A1 Diamido thiazole derivatives as protein kinase inhibitors |
| 08/18/2010 | EP2217594A2 Novel pyrimidine derivatives |
| 08/18/2010 | EP2217593A1 1,2,4,-triazin-3,5-dione compounds for treating disorders that respond to modulation of the dopamine d3 receptor |
| 08/18/2010 | EP2217592A1 Biphenyl derivatives as modulators of the histamine-h3 receptor useful for the treatment of disorders related thereto |
| 08/18/2010 | EP2217590A1 Pyridopyrimidine derivatives as pi3 kinase inhibitors |
| 08/18/2010 | EP2217589A2 Modulators of ocular oxidative stress |
| 08/18/2010 | EP2217588A1 Inhibitors of histone deacetylase |
| 08/18/2010 | EP2217583A1 Benzenesulfonanilide compounds suitable for treating disorders that respond to modulation of the serotonin 5-ht6 receptor |
| 08/18/2010 | EP2217582A1 Crystalline hydrate of betamimetika and use as medicament thereof |
| 08/18/2010 | EP2217581A1 Substituted cyclopentanes having prostaglanding activity |
| 08/18/2010 | EP2217580A2 Substituted tetrazole compounds and uses thereof |
| 08/18/2010 | EP2217576A2 Benzodiazepinone compounds useful in the treatment of skin conditions |
| 08/18/2010 | EP2217575A1 Arylindenopyrimidines and their use as adenosine a2a receptor antagonists |
| 08/18/2010 | EP2217572A1 Isoquinoline modulators of atp-binding cassette transporters |
| 08/18/2010 | EP2217568A1 Compounds for inhibiting ksp kinesin activity |
| 08/18/2010 | EP2217566A1 Bis-(sulfonylamino) derivatives in therapy 066 |
| 08/18/2010 | EP2217565A1 Compounds which modulate the cb2 receptor |
| 08/18/2010 | EP2217564A1 Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| 08/18/2010 | EP2217562A2 Crystal forms of o-desmethylvenlafaxine fumarate |
| 08/18/2010 | EP2217549A2 Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors |
| 08/18/2010 | EP2217275A2 Pharmaceutical compositon for cleansing of the bowel |
| 08/18/2010 | EP2217273A1 Methods and compositions for regulating airway tissue remodelling |
| 08/18/2010 | EP2217259A2 Methods for treatment of thiol-containing compound deficient conditions |
| 08/18/2010 | EP2217258A1 Methods of using interleukin-1 receptor antagonist as a myeloprotective agent |
| 08/18/2010 | EP2217256A2 Compositon for enhancing immunity |
| 08/18/2010 | EP2217255A2 Use of phytoecdysones in the preparation of a composition for acting on metabolic syndrome |
| 08/18/2010 | EP2217250A2 Immunomodulating compounds and related compositions and methods |
| 08/18/2010 | EP2217249A1 Inhibition of versican with sirna and other molecules |
| 08/18/2010 | EP2217247A1 Novel synthesis of beta-nucleosides |
| 08/18/2010 | EP2217245A1 The use of (3-amino-2-fluoropropyl) phosphinic acid for treatment of nerd |
| 08/18/2010 | EP2217242A1 Methods of use |
| 08/18/2010 | EP2217241A2 Wet granulation using a water sequestering agent |
| 08/18/2010 | EP2217240A1 Methods and compounds for preventing and treating a tumour |
| 08/18/2010 | EP2217239A2 Modulation of protein trafficking |
| 08/18/2010 | EP2217238A2 Methods and compositions for the treatment of proteinuric diseases |
| 08/18/2010 | EP2217237A1 Aryl-substituted bridged or fused diamines as modulators of leukotriene a4 hydrolase |
| 08/18/2010 | EP2217236A1 Use of lobeline epimers in the treatment of central nervous system diseases, pathologies, and drug abuse |
| 08/18/2010 | EP2217235A2 Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| 08/18/2010 | EP2217234A2 Combinations of mek inhibitors with mtor inhibitors |
| 08/18/2010 | EP2217233A1 Methods and compositions for treating hepatic diseases |
| 08/18/2010 | EP2217232A1 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid - 465 |
| 08/18/2010 | EP2217231A1 Use of 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives in leukemia management |
| 08/18/2010 | EP2217229A1 Pharmaceutical compositions for modulating a kinase cascade and methods of use thereof |
| 08/18/2010 | EP2217228A1 Solid pharmaceutical composition comprising tamsulosin |
| 08/18/2010 | EP2217227A2 Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents |
| 08/18/2010 | EP2217225A2 Pharmaceutical composition containing micronized particles of naphthoquinone-based compound |
| 08/18/2010 | EP2217224A1 Lipid compounds for use in cosmetic products, as food supplement or as a medicament |
| 08/18/2010 | EP2217223A2 Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| 08/18/2010 | EP2217220A1 Lipoic acid pellet composition |
| 08/18/2010 | EP2217219A2 A sublingual effervescent tablet of progesterone associated with cyclodextrin |
| 08/18/2010 | EP2217217A1 Controlled release pharmaceutical compositions of pregabalin |
| 08/18/2010 | EP2217216A1 Formulations for enhanced bioavailability of orally administered polar agents |
| 08/18/2010 | EP2217214A2 Pharmaceutical formulation comprising ezetimibe |
| 08/18/2010 | EP2217212A1 Pharmaceutical solid hybrids |
| 08/18/2010 | EP2217210A2 Sustained release tablets with hydromorphone |
| 08/18/2010 | EP2217209A1 Novel thermosensitive liposomes containing therapeutic agents |
| 08/18/2010 | EP2217207A1 Fast release solid formulation, preparation and use thereof |
| 08/18/2010 | EP2217205A1 Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor |
| 08/18/2010 | EP2217204A2 Compositions for the topical protection of the ocular tissues from the damaging effects of ultraviolet radiations |
| 08/18/2010 | EP2217202A2 Oral care product and methods of use and manufacture thereof |
| 08/18/2010 | EP2217073A1 Method of treating metabolic disorders and depression with dopamine receptor agonists |
| 08/18/2010 | EP2217071A1 Antifungal agents |
| 08/18/2010 | EP2217070A1 Nucleic acid fluorescent stains |
| 08/18/2010 | EP2217068A1 NOVEL sEH INHIBITORS AND THEIR USE |
| 08/18/2010 | EP2217067A1 Method and compounds for modulating insulin production |
| 08/18/2010 | EP2217062A1 Multi-targeted rnai therapeutics for scarless wound healing of skin |
| 08/18/2010 | EP2076495B1 Quinoline derivatives with 5-ht-binding properties |
| 08/18/2010 | EP2066677B1 Pyridooxazepine progesteron receptor modulators |
| 08/18/2010 | EP2041104B1 Cinnamoyl-piperazine derivatives and their use as par- i antagonists |
| 08/18/2010 | EP2013191B1 3,7-diamino-10h-phenothiazine salts and their use |
| 08/18/2010 | EP1984350B1 Pyrimidine derivatives used as pi-3 kinase inhibitors |
| 08/18/2010 | EP1979355B1 Spiro imidazole derivatives as ppar modulators |
| 08/18/2010 | EP1951692B1 Oxazole and thiazole ppar modulator |
| 08/18/2010 | EP1940828B1 Heterocyclic aspartyl protease inhibitors |
| 08/18/2010 | EP1940786B1 Biphenyl derivatives and their use in treating hepatitis c |
| 08/18/2010 | EP1934203B1 3,4-dihydro-2H-benzo[1,4]oxazine and 3,4-dihydro-2H-benzo[1,4]thiazine COMPOUNDS AS ALPHA2C ADRENORECEPTOR AGONISTS |
| 08/18/2010 | EP1928459B1 Tablet-type controlled-release preparation containing cinnarizine and dimenhydrinate for combating vertigo |